Core #1 Chemistry Dr. Wei Wang, Ph.D. The Chemistry core functions in the Division of Molecular Imaging and in this NTR consortium to (i) provide the ability to develop new molecularly targeting entities for both nuclear and optical imaging;(ii) develop the validated analytical tools necessary for new agents;and (iii) provide assistance in manufacture. New targeting entities Dr. Wei Wang's expertise and demonstrated innovation is evident in the small animal imaging results presented in Section 5.C.4,5 regarding the c(KRGD) and c(KAHWGFLD) dual labeled imaging agents. The following provides an example of her emerging work with Dr. Charles Brunicardi to develop an optical substrate for imaging vTK gene expression. [18F]-FHBG and other isotope substrates have been used along with several other TK substrates [143-145]. Although [18F]-FHBG is currently approved as an investigational drug for human studies [146], its short half life (2 h) may be responsible for the high background in small animal imaging. For example, in studies to track vTK expressing tumor cells, investigators routinely use subcutaneous tumor implantation on the shoulder of animals. One hour after administration, incomplete clearance prevents distinguishing tumor cells within the trunk of the animal. In addition, isotopically labeled agents are not widely available to the biomedical research community. For this reason, Dr. Wei Wang developed three optical analogs of FHBG depicted in Fig. 43 that are conjugated to NIR dye IR783 that is synthesized in-house. It is noteworthy that the second compound, could be developed as a potential dual labeled PET and optical imaging agent by replacing cold fluorine with 18F.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-9)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Health Science Center Houston
United States
Zip Code
Rasmussen, John C; Aldrich, Melissa B; Tan, I-Chih et al. (2016) Lymphatic transport in patients with chronic venous insufficiency and venous leg ulcers following sequential pneumatic compression. J Vasc Surg Venous Lymphat Disord 4:9-17
Gonzalez-Garay, M L; Aldrich, M B; Rasmussen, J C et al. (2016) A novel mutation in CELSR1 is associated with hereditary lymphedema. Vasc Cell 8:1
Zhu, Banghe; Rasmussen, John C; Litorja, Maritoni et al. (2016) Determining the Performance of Fluorescence Molecular Imaging Devices Using Traceable Working Standards With SI Units of Radiance. IEEE Trans Med Imaging 35:802-11
Wang, Xuejuan; Aldrich, Melissa B; Yang, Zhi et al. (2016) Influence of chelator and near-infrared dye labeling on biocharacteristics of dual-labeled trastuzumab-based imaging agents. Chin J Cancer Res 28:362-9
Zhu, B; Sevick-Muraca, E M (2015) A review of performance of near-infrared fluorescence imaging devices used in clinical studies. Br J Radiol 88:20140547
Gao, Peng; Pinkston, Kenneth L; Wilganowski, Nathaniel et al. (2015) Deglycosylation of mAb by EndoS for improved molecular imaging. Mol Imaging Biol 17:195-203
Rasmussen, John C; Fife, Caroline E; Sevick-Muraca, Eva M (2015) Near-Infrared Fluorescence Lymphatic Imaging in Lymphangiomatosis. Lymphat Res Biol 13:195-201
Ghosh, Sukhen C; Pinkston, Kenneth L; Robinson, Holly et al. (2015) Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates. Nucl Med Biol 42:177-83
Agollah, Germaine D; Gonzalez-Garay, Manuel L; Rasmussen, John C et al. (2014) Evidence for SH2 domain-containing 5'-inositol phosphatase-2 (SHIP2) contributing to a lymphatic dysfunction. PLoS One 9:e112548
Rasmussen, John C; Herbst, Karen L; Aldrich, Melissa B et al. (2014) An abnormal lymphatic phenotype is associated with subcutaneous adipose tissue deposits in Dercum's disease. Obesity (Silver Spring) 22:2186-92

Showing the most recent 10 out of 33 publications